Performance data Clinical studies Patient preferences

Patient preference

Any company developing a new inhaler has to carefully prove patient acceptance. In this section, you find summaries of studies proving that Respimat® SMI is preferred by patients compared to other inhalers.

Click on the links below each summary to order a printed abstract of the study for free.

  • Reviews

    Hodder R, Price D. Patient Preference for Inhaler Devices in Chronic Obstructive Pulmonary Disease: Experience with Respimat® Soft Mist Inhaler. Int J Chronic Obstruct Pulm Dis, Vol 4, 2009, Pp 381-390

  • Preference of Respimat® SMI vs DPIs

    Hodder R et al. Asthma Patients Prefer Respimat® Soft Mist Inhaler to Turbohaler. Int J Chronic Obstruct Pulm Dis, Vol 4, 2009, Pp225-232

    Hodder R et al. Asthma Patients Prefer Respimat® Soft Mist™ Inhaler (SMI) to Turbuhaler® J Aerosol Med, Vol 20, Nr 2, 2007, P 204

    In this psychometric evaluation device performance and convenience as well as preference and willingness to continue using the device with Respimat® SMI and Turbuhaler® was investigated with a validated questionnaire (Patient Satisfaction and Prefernece Questionnaire (PASAPQ)). The aim was to assess patients´ perception of handling and satisfaction with the two devices. Adult asthmatic patients who used Respimat® SMI and Turbuhaler® devices in a clinical setting reported significantly greater satisfaction with Respimat® SMI. The majority of patients preffered Respimat® SMI to Turbuhaler® and patients were more willing to continue using Respimat® SMI than Turbuhaler®.

    Freytag et al. Respimat® Soft Mist™ inhaler preferred to Diskus® by Patients with COPD and /or Asthma Abstract ATS 2007

    This observational study looked at patient satisfaction and preference comparing Respimat® Soft Mist™ Inhaler (SMI) and Diskus® by using a validated questionnaire (Patient Satisfaction and Preference Questionnaire (PASAPQ)) in 150 asthma and COPD patients in Germany. Total Satisfactions score, as well as device performance score and convenience score rated significantly higher for Respimat® SMI. The largest differences in satisfaction ratings in favour of Respimat® SMI related to aspects of inhalation and the speed emmited from the device. The vast majority of patients preferred Respimat® SMI to the Diskus® .

  • Improving inhaler use in COPD and the role of patient preference

    European Respiratory Review (Volume 14, Review 96, December 2005)

    The purpose of this review was to consider the subjects of inhaler use and selection in COPD, and how compliance and treatment outcomes might improve by taking patient preference into account. In order to get a comprehensive overview on this topic a round table meeting, sponsored by Boehringer Ingelheim was held. The discussions were broken down into the following categories:

     

    • E.D. Bateman
      Improving Inhaler Use in COPD And The Role Of Patient Preference
    • L.M. Osman and M.E. Hyland
      Patient Needs And Medication Styles In COPD
    • R. Booker
      Effective Communication With The Patient
    • C.S. Rand
      Patient Adherence With COPD Therapy
    • S.P. Newman
      Inhaler Treatment Options In COPD
    • P.Anderson
      Patient Preference For And Satisfaction With Inhaler Devices
    • K.R. Chapman, T.H. Voshaar, C. Virchow
      Inhaler Choice In the Primary Practice
  • Preference of Respimat® SMI over pMDIs

    Kozma CM et al. Development and validation of patient satisfaction and preference questionnaire for inhalation devices. Treat Respir Med 2005; 4: 41-52

    This study assesses the validation, reliability and responsiveness of a newly developed Patient Satisfaction and Preference Questionnaire (PASAPQ) on inhaler devices to be easily understood by asthma and COPD patients. The analysis has proven that PASAPQ is a practical, valid, reliable and responsive instrument for measuring respiratory device satisfaction.

    Schuermann W. Schmidtmann S., Moroni P, Massey D, Qidan M. Respimat® Soft Mist™ Inhaler versus hydrofluroalkane medered dose inhaler: patient preference and satisfaction. Treatm. Respir. Med.2005; 4: 53-61

    This study describes patients' experience regarding handling, satisfaction and preference of Respimat® Soft Mist™ Inhaler over pMDIs. The overall satisfaction for Respimat® SMI was extremely high. This resulted in a clear preference of Respimat® over the pMDIs.

    Hodder R, Schürmann W, Moroni P, Barczok M. Patients with obstructive lung diseases prefer Respimat® Soft Mist™ Inhaler tp pMDIs. Chest 2004; 126(4)(Suppl): 806s

    This abstract deals with pooled data from three studies assessing patients' experience regarding satisfaction, preference and willingness to continue with Respimat® SMI vs pMDIs. In the three studies the vast majority of patients preferred Respimat® SMI to the pMD.

    Schürmann W, Barczok M, Timmer W, Pfaff HP, Hodder R. Preference for novel soft mist inhaler over pMDI in patients with COPD.Eur Respir J 2004; 24(Suppl 48): 88s abstract: P649

    This study describes patients' experience regarding handling, satisfaction and preference of Respimat® Soft Mist™ Inhaler over pMDIs. The overall satisfaction for Respimat® SMI was extremely high. This resulted in a clear preference of Respimat® over the pMDIs.

Back to top